The investigation established the feasibility and safety of growing mesenchymal stem cells (MSCs) in space for human clinical applications.Abba Zubair, Director of Transfusion Medicine and Stem Cell Therapy at the Mayo Clinic, were published in the journal Nature Microgravity. Results from an ISS National Lab-sponsored investigation led by principal investigator Dr.Additional research and long-term clinical follow-up will be needed to guide future clinical trials on stem cell therapy for heart failure.įor background on how Mayo began this effort click through to " Mayo Clinic and Collaborators Develop New Tool for Transplanting Stem Cells. That research translated into clinical studies engaging multiple trans-Atlantic collaborations charting the development pathway for advanced regenerative therapies. This study is the culmination of research going back 20 years, beginning with the discovery of the cardiopoiesis process at Mayo Clinic. There are no therapies to reverse the damage from heart failure, and the long-term prognosis is poor. and is a leading cause of death, according to the National Institutes of Health. Heart failure affects approximately 5.7 million people in the U.S. One of the contributors is coronary artery disease in which plaque buildup causes a narrowing of arteries. Heart failure is a common condition in which the body is not able to pump enough blood to maintain healthy cardiovascular function. "These patients showed reduced risk of death or hospitalization after cardiopoietic stem cell therapy."Ĭardiopoietic cells, discovered at Mayo Clinic, are derived from adult stem cell sources, typically of bone marrow origin, and have shown potential to heal failing hearts. "Analyses suggest that cardiopoietic stem cell therapy on top of standard-of-care therapy principally benefits a subgroup of heart failure patients suffering from advanced disease characterized by enlargement of the left ventricle," says Dr. Researchers followed both groups for two years to better understand the long-term outcome of stem cell therapy. Cardiopoietic cells, discovered at Mayo Clinic, are derived from adult stem cell sources, typically of bone marrow origin, and have shown potential to heal failing hearts. The results were compared to the control group in which a placebo was given with standard treatment for heart failure. In one group, researchers studied cardiopoietic stem cell therapy added to standard of care treatment for heart failure. The Congestive Heart Failure Cardiopoietic Regenerative Therapy trial, known as CHART-1, enrolled 315 heart failure patients from 39 medical centers across 10 countries. Identifying means to preselect for those that will benefit is therefore needed." Some respond particularly well whereas, others show only a neutral outcome. "Notably, though, not all patients with heart failure respond uniformly to stem cell therapy. "Optimizing the reparative functionality of patient-derived stem cells is promising," says Dr. and Mary Sue Shannon Family Director for Regenerative Medicine, as well as the Marriott Family Director of Comprehensive Cardiac Regenerative Medicine for the Center for Regenerative Medicine and the Marriott Family Professor in Cardiovascular Research. Andre Terzic, M.D., Ph.D., the the Michael S.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |